Dianthus Therapeutics, Inc.
DNTHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dianthus Therapeutics, Inc. focuses on Biotechnology services and products. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. The $5.77B market capitalization puts DNTH squarely in mid-cap range for its industry. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Market Cap
$5.77B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
-22.70
EPS (TTM)
$-4.69
EPS (Fwd)
$-4.65
ROE
-22.7%
ROA
-15.0%
Cash
$1.11B
Total Debt
$1.4M
Free CF
-$71.0M
52W Change
417.6%
Annual Financials
Cash vs Debt
Dianthus Therapeutics, Inc. holds $1.11B in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$71.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -22.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $6.4M (2022) to $2.0M (2025), a 68% decline worth watching.
With a beta below 0.7, Dianthus Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DNTH.